OBJECTIVE: The aim of this study was to evaluate the safety and efficacy of black cohosh and red clover compared with placebo for the relief of menopausal vasomotor symptoms. METHODS: This study was a randomized, four-arm, double-blind clinical trial of standardized black cohosh, red clover, placebo, and 0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate (CEE/MPA; n = 89). Primary outcome measures were reduction in vasomotor symptoms (hot flashes and night sweats) by black cohosh and red clover compared with placebo; secondary outcomes included safety evaluation, reduction of somatic symptoms, relief of sexual dysfunction, and overall improvement in quality of life. RESULTS: Reductions in number of vasomotor symptoms after a 12-month intervention were as follows: black cohosh (34%), red clover (57%), placebo (63%), and CEE/MPA (94%), with only CEE/MPA differing significantly from placebo. Black cohosh and red clover did not significantly reduce the frequency of vasomotor symptoms as compared with placebo. Secondary measures indicated that both botanicals were safe as administered. In general, there were no improvements in other menopausal symptoms. CONCLUSIONS: Compared with placebo, black cohosh and red clover did not reduce the number of vasomotor symptoms. Safety monitoring indicated that chemically and biologically standardized extracts of black cohosh and red clover were safe during daily administration for 12 months.
RCT Entities:
OBJECTIVE: The aim of this study was to evaluate the safety and efficacy of black cohosh and red clover compared with placebo for the relief of menopausal vasomotor symptoms. METHODS: This study was a randomized, four-arm, double-blind clinical trial of standardized black cohosh, red clover, placebo, and 0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate (CEE/MPA; n = 89). Primary outcome measures were reduction in vasomotor symptoms (hot flashes and night sweats) by black cohosh and red clover compared with placebo; secondary outcomes included safety evaluation, reduction of somatic symptoms, relief of sexual dysfunction, and overall improvement in quality of life. RESULTS: Reductions in number of vasomotor symptoms after a 12-month intervention were as follows: black cohosh (34%), red clover (57%), placebo (63%), and CEE/MPA (94%), with only CEE/MPA differing significantly from placebo. Black cohosh and red clover did not significantly reduce the frequency of vasomotor symptoms as compared with placebo. Secondary measures indicated that both botanicals were safe as administered. In general, there were no improvements in other menopausal symptoms. CONCLUSIONS: Compared with placebo, black cohosh and red clover did not reduce the number of vasomotor symptoms. Safety monitoring indicated that chemically and biologically standardized extracts of black cohosh and red clover were safe during daily administration for 12 months.
Authors: J Liu; J E Burdette; H Xu; C Gu; R B van Breemen; K P Bhat; N Booth; A I Constantinou; J M Pezzuto; H H Fong; N R Farnsworth; J L Bolton Journal: J Agric Food Chem Date: 2001-05 Impact factor: 5.279
Authors: Cheri L Van Patten; Ivo A Olivotto; G Keith Chambers; Karen A Gelmon; T Gregory Hislop; Edith Templeton; Angela Wattie; Jerilynn C Prior Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Gail B Mahady; Tieraona Low Dog; Marilyn L Barrett; Mary L Chavez; Paula Gardiner; Richard Ko; Robin J Marles; Linda S Pellicore; Gabriel I Giancaspro; Dandapantula N Sarma Journal: Menopause Date: 2008 Jul-Aug Impact factor: 2.953
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Kelly A Shipkowski; Joseph M Betz; Linda S Birnbaum; John R Bucher; Paul M Coates; D Craig Hopp; Duffy MacKay; Hellen Oketch-Rabah; Nigel J Walker; Cara Welch; Cynthia V Rider Journal: Food Chem Toxicol Date: 2018-04-04 Impact factor: 6.023
Authors: Jinghu Li; Tanja Gödecke; Shao-Nong Chen; Ayano Imai; David C Lankin; Norman R Farnsworth; Guido F Pauli; Richard B van Breemen; Dejan Nikolić Journal: Xenobiotica Date: 2011-08-09 Impact factor: 1.908
Authors: Christopher R S Banerji; Maryna Panamarova; Johanna Pruller; Nicolas Figeac; Husam Hebaishi; Efthymios Fidanis; Alka Saxena; Julian Contet; Sabrina Sacconi; Simone Severini; Peter S Zammit Journal: Hum Mol Genet Date: 2019-04-15 Impact factor: 6.150
Authors: Luying Chen; Jaewoo Choi; Scott W Leonard; Suzanne Banuvar; Elena Barengolts; Marlos Viana; Shao-Nong Chen; Guido F Pauli; Judy L Bolton; Richard B van Breemen Journal: J Agric Food Chem Date: 2020-11-16 Impact factor: 5.279